NCT03739125View on ClinicalTrials.gov

Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

November 7, 2017

Primary Completion Date

May 25, 2020

Study Completion Date

December 2, 2020

Conditions
Type2 Diabetes
Interventions
DRUG

CKD-501 0.5mg

CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745

DRUG

Placebo

orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745

Trial Locations (1)

Unknown

Severance Hospital, Yonsei University Health System, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY